Tous Actualités
Suivre
Abonner Intercell AG

Intercell AG

euro adhoc: Intercell AG
other
First child vaccinated with Intercell Japanese Encephalitis (JE) Vaccine in India - Pediatric Phase II clinical trial started

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
Research & Development
16.07.2007
» Development process for vaccine launch in endemic countries 
accelerated -   First child vaccinated with IC51 » First 
administration of Intercell´s JE vaccine to children - Results of   
Phase II trial are expected in late 2007 » Development plan for 
endemic regions clearly defined - Market launch   expected in 2009
Vienna (Austria), July 16, 2007 - Intercell AG and its partner 
Biological E. Ltd. (Hyderabad, India) announced today that the 
companies have started a pediatric Phase II clinical trial for 
Intercell´s novel Japanese Encephalitis Vaccine in India.
The randomized and controlled study aims to demonstrate the dose, 
safety and immunogenicity of Intercell´s JE vaccine compared to a 
locally available, Korean made mouse-brain Japanese Encephalitis 
vaccine. The study will enroll 60 children at the age of one to three
years. It is the first step toward the licensure of a new cell 
culture derived product in Asia, which is expected in 2009.
"The start of the pediatric clinical trials in India is a major step 
forward to make our vaccine, which is based on a proven and safe 
technology, available also for the population, and especially the 
children, in endemic regions," states Gerd Zettlmeissl, Chief 
Executive Officer of Intercell AG.
Vijay Kumar Datla, Chairman and Managing Director of Biological E. 
Ltd added, "With the spirit and energy of this partnership we aim to 
make equitable access to this important intervention against JE 
available in the endemic regions of the world. This trial will be 
followed by a corresponding Phase III study in both children and 
adults in India."
About Intercell´s investigational JE vaccine (IC51) Intercell´s novel
investigational JE vaccine is a purified, inactivated vaccine for 
active immunization against the Japanese Encephalitis virus. With 
over 3 billion people living in endemic areas, Japanese Encephalitis,
a mosquito-borne flaviviral infection, is the leading cause of 
childhood encephalitis and viral encephalitis in Asia.
In successfully concluded pivotal Phase III trials, Intercell´s 
Japanese Encephalitis vaccine (IC51) demonstrated a favorable safety 
and immunogenicity profile:
» The immunogenicity of IC51 was at least as good as the U.S. 
licensed   product, JE-VAX® » IC51 demonstrated an overall clinical 
safety profile similar to placebo » Further, IC51 showed an excellent
local tolerability profile in this head-to-   head study with JE-VAX®
Intercell´s novel JE vaccine, manufactured in the company´s 
proprietary manufacturing facility in Scotland, is prepared using 
tissue culture rather than live organisms and, unlike JE-VAX®, does 
not contain any stabilizers such as gelatin or preservatives in its 
formulation.
On June 13, 2006, Novartis and Intercell announced that the companies
had reached an agreement for Novartis to acquire marketing and 
distribution rights for Intercell´s Japanese Encephalitis Virus 
Vaccine in the United States, Europe and certain other markets in 
Asia and Latin America.
About Biological E. Ltd Over the last 50 years, Biological E. Ltd. 
(BE) has been a leading vaccine and pharmaceutical company. The 
company produces a range of critical vaccines and has been an active 
partner in the National Immunization Program of India. The company is
currently commissioning large-scale cGMP facilities in order increase
its capacities and product range to offer these vaccines on a global 
basis. In addition to its current pipeline of combination vaccines 
that are entering pivotal trials, BE has R&D programs to develop 
novel vaccines for both vector-borne and enteric diseases. The 
company has entered into a number of strategic collaborations with 
leading biotech companies and research institutes for basic R&D.  
Biological E. is a privately held company. Biological E will 
manufacture Intercell´s JE vaccine for the Asian markets and will 
exclusively market and distribute the product in India, Nepal, Bhutan
and Bangladesh. For more information please visit: 
www.biologicale.com
end of announcement                               euro adhoc 16.07.2007 07:55:00

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market

Plus de actualités: Intercell AG
Plus de actualités: Intercell AG